Search research articles
Contact Us
Filters
Showing results (301-310 of 419) with videos related to
Page
of 42
Sort By:
Neurology
|
May 30, 2002
Long-term response to zonisamide in patients with West syndrome
Y Suzuki, K Imai, Y Toribe, et al.
Nature Genetics
|
November 8, 2016
Clonal evolution of chemotherapy-resistant urothelial carcinoma
Bishoy M Faltas, Davide Prandi, Scott T Tagawa, et al.
European Urology
|
September 6, 2024
Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [<sup>177</sup>Lu]Lu-PSMA-617 in the Phase 3 VISION Trial
Andrew J Armstrong, Oliver Sartor, Johann de Bono, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 17, 2015
The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer
Himisha Beltran, Adam Jendrisak, Mark Landers, et al.
Neurology
|
May 5, 1998
Gender-related penetrance and de novo GTP-cyclohydrolase I gene mutations in dopa-responsive dystonia
Y Furukawa, A E Lang, J M Trugman, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 17, 2019
Clinical features of neuroendocrine prostate cancer
Vincenza Conteduca, Clara Oromendia, Kenneth W Eng, et al.
ESMO Open
|
December 23, 2021
Assessment of the albumin-bilirubin grade as a prognostic factor in patients with non-small-cell lung cancer receiving anti-PD-1-based therapy
K Takada, S Takamori, M Shimokawa, et al.
Revista Espanola De Medicina Nuclear E Imagen Molecular
|
May 22, 2025
Revolutionizing prostate cancer treatment: PSMA-targeted therapy in modern therapeutics
A Ricaurte-Fajardo, V Marulanda-Corzo, S Ruder, et al.
Cancer Research
|
July 30, 2011
Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer
Medha S Darshan, Matthew S Loftus, Maria Thadani-Mulero, et al.
Urologic Oncology
|
July 1, 2020
Phase I trial of docetaxel plus lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (<sup>177</sup>Lu-J591) for metastatic castration-resistant prostate cancer
Jaspreet S Batra, Muhammad Junaid Niaz, Young E Whang, et al.
Page
of 42
Search research articles
Search
Showing results (301-310 of 419) with videos related to
Sort By:
Page
of 42
Neurology
|
May 30, 2002
Long-term response to zonisamide in patients with West syndrome
Y Suzuki, K Imai, Y Toribe, et al.
Nature Genetics
|
November 8, 2016
Clonal evolution of chemotherapy-resistant urothelial carcinoma
Bishoy M Faltas, Davide Prandi, Scott T Tagawa, et al.
European Urology
|
September 6, 2024
Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [<sup>177</sup>Lu]Lu-PSMA-617 in the Phase 3 VISION Trial
Andrew J Armstrong, Oliver Sartor, Johann de Bono, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 17, 2015
The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer
Himisha Beltran, Adam Jendrisak, Mark Landers, et al.
Neurology
|
May 5, 1998
Gender-related penetrance and de novo GTP-cyclohydrolase I gene mutations in dopa-responsive dystonia
Y Furukawa, A E Lang, J M Trugman, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 17, 2019
Clinical features of neuroendocrine prostate cancer
Vincenza Conteduca, Clara Oromendia, Kenneth W Eng, et al.
ESMO Open
|
December 23, 2021
Assessment of the albumin-bilirubin grade as a prognostic factor in patients with non-small-cell lung cancer receiving anti-PD-1-based therapy
K Takada, S Takamori, M Shimokawa, et al.
Revista Espanola De Medicina Nuclear E Imagen Molecular
|
May 22, 2025
Revolutionizing prostate cancer treatment: PSMA-targeted therapy in modern therapeutics
A Ricaurte-Fajardo, V Marulanda-Corzo, S Ruder, et al.
Cancer Research
|
July 30, 2011
Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer
Medha S Darshan, Matthew S Loftus, Maria Thadani-Mulero, et al.
Urologic Oncology
|
July 1, 2020
Phase I trial of docetaxel plus lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (<sup>177</sup>Lu-J591) for metastatic castration-resistant prostate cancer
Jaspreet S Batra, Muhammad Junaid Niaz, Young E Whang, et al.
Page
of 42